A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Accompanied by a Comparative Study of Cellular Metabolism in Subjects With Pulmonary Hypertension With and Without Right Ventricular Dysfunction
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Ranolazine (Primary)
- Indications Pulmonary hypertension; Right ventricular dysfunction
- Focus Therapeutic Use
- 22 Jun 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2018.
- 22 Jun 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2018.
- 29 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Feb 2017.